Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease
暂无分享,去创建一个
Brian J. Bacskai | Matthew P. Frosch | Rebecca A. Betensky | Steven M. Greenberg | M. Frosch | S. Greenberg | C. Prada | M. Garcia-Alloza | B. Bacskai | R. Betensky | Susan Raju | Monica Garcia-Alloza | S. Raju | Elissa M. Robbins | Sandy X. Zhang-Nunes | Susan M. Purcell | Claudia Prada | Sandy Zhang-Nunes | S. M. Purcell | Sandy X. Zhang-Nunes
[1] D. Selkoe,et al. The ups and downs of Aβ , 2006, Nature Medicine.
[2] J. Hardy,et al. Amyloid at the blood vessel wall , 2006, Nature Medicine.
[3] Rebecca A Betensky,et al. Kinetics of Cerebral Amyloid Angiopathy Progression in a Transgenic Mouse Model of Alzheimer Disease , 2006, The Journal of Neuroscience.
[4] M. Frosch,et al. The Cerebral β‐Amyloid Angiopathies: Hereditary and Sporadic , 2006 .
[5] Brian J Bacskai,et al. Progression of Cerebral Amyloid Angiopathy in Transgenic Mouse Models of Alzheimer Disease , 2005, Journal of neuropathology and experimental neurology.
[6] D. Borchelt,et al. Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer's disease: Relationships to β-amyloid deposition and neurotransmitter abnormalities , 2005, Neurobiology of Disease.
[7] Jian Xu,et al. Matrix metalloproteinase-9 in cerebral-amyloid-angiopathy-related hemorrhage , 2005, Journal of the Neurological Sciences.
[8] F. Bloom,et al. Mouse models of human neurodegenerative disorders: requirements for medication development. , 2005, Archives of neurology.
[9] W. H. Jordan,et al. Exacerbation of Cerebral Amyloid Angiopathy-Associated Microhemorrhage in Amyloid Precursor Protein Transgenic Mice by Immunotherapy Is Dependent on Antibody Recognition of Deposited Forms of Amyloid β , 2005, The Journal of Neuroscience.
[10] R. Weller,et al. Cerebrovascular disease and the pathophysiology of Alzheimer's disease. Implications for therapy. , 2004, Panminerva medica.
[11] H. Tanila,et al. Longitudinal observation on CSF Aβ42 levels in young to middle-aged amyloid precursor protein/presenilin-1 doubly transgenic mice , 2004, Neurobiology of Disease.
[12] D. Borchelt,et al. APP processing and amyloid deposition in mice haplo-insufficient for presenilin 1 , 2004, Neurobiology of Aging.
[13] R. Weller,et al. Cerebral amyloid angiopathy plays a direct role in the pathogenesis of Alzheimer’s disease Pro-CAA position statement , 2004, Neurobiology of Aging.
[14] Joanna L. Jankowsky,et al. Mutant presenilins specifically elevate the levels of the 42 residue β-amyloid peptide in vivo: evidence for augmentation of a 42-specific γ secretase , 2004 .
[15] D. German,et al. Mouse Models of Alzheimer's Disease: Insight into Treatment , 2004, Reviews in the neurosciences.
[16] J. Kemp,et al. PS2APP Transgenic Mice, Coexpressing hPS2mut and hAPPswe, Show Age-Related Cognitive Deficits Associated with Discrete Brain Amyloid Deposition and Inflammation , 2003, The Journal of Neuroscience.
[17] M. Mattson,et al. Triple-Transgenic Model of Alzheimer's Disease with Plaques and Tangles Intracellular Aβ and Synaptic Dysfunction , 2003, Neuron.
[18] D. Borchelt,et al. Normal cognitive behavior in two distinct congenic lines of transgenic mice hyperexpressing mutant APPSWE , 2003, Neurobiology of Disease.
[19] Brian J Bacskai,et al. In Vivo Imaging of Reactive Oxygen Species Specifically Associated with Thioflavine S-Positive Amyloid Plaques by Multiphoton Microscopy , 2003, The Journal of Neuroscience.
[20] B. Reisberg,et al. Vascular cognitive impairment , 2005, Journal of Neurology, Neurosurgery & Psychiatry.
[21] K. Jellinger,et al. Alzheimer disease and cerebrovascular pathology: an update , 2002, Journal of Neural Transmission.
[22] D. Borchelt,et al. Accumulation of proteolytic fragments of mutant presenilin 1 and accelerated amyloid deposition are co-regulated in transgenic mice , 2002, Neurobiology of Aging.
[23] J. Hardy,et al. Enhanced Neurofibrillary Degeneration in Transgenic Mice Expressing Mutant Tau and APP , 2001, Science.
[24] D. Borchelt,et al. Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. , 2001, Biomolecular engineering.
[25] M. Moskowitz,et al. Structural and functional disruption of vascular smooth muscle cells in a transgenic mouse model of amyloid angiopathy. , 2001, The American journal of pathology.
[26] M. Staufenbiel,et al. Spontaneous Hemorrhagic Stroke in a Mouse Model of Cerebral Amyloid Angiopathy , 2001, The Journal of Neuroscience.
[27] B T Hyman,et al. Growth Arrest of Individual Senile Plaques in a Model of Alzheimer's Disease Observed by In Vivo Multiphoton Microscopy , 2001, The Journal of Neuroscience.
[28] Mikio Shoji,et al. Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease , 2001, The Journal of Neuroscience.
[29] D. Flood,et al. Presenilin-1 P264L Knock-In Mutation: Differential Effects on Aβ Production, Amyloid Deposition, and Neuronal Vulnerability , 2000, The Journal of Neuroscience.
[30] K. Duff,et al. Quantitative histological analysis of amyloid deposition in Alzheimer’s double transgenic mouse brain , 2000, Neuroscience.
[31] R. Weller,et al. Cerebral Amyloid Angiopathy: Accumulation of Aβ in Interstitial Fluid Drainage Pathways in Alzheimer's Disease , 2000, Annals of the New York Academy of Sciences.
[32] H. Vanderstichele,et al. Presenilin 2 deficiency causes a mild pulmonary phenotype and no changes in amyloid precursor protein processing but enhances the embryonic lethal phenotype of presenilin 1 deficiency. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[33] D. Selkoe,et al. The cell biology of β-amyloid precursor protein and presenilin in Alzheimer's disease , 1998 .
[34] L. Mucke,et al. Isoform-specific effects of human apolipoprotein E on brain function revealed in ApoE knockout mice: increased susceptibility of females. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[35] J. Hardy,et al. Increased Aβ42(43) from cell lines expressing presenilin 1 mutations , 1998, Annals of neurology.
[36] J. Hardy,et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes , 1998, Nature Medicine.
[37] B. Sommer,et al. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[38] J. Hardy,et al. Increased amyloid-β42(43) in brains of mice expressing mutant presenilin 1 , 1996, Nature.
[39] S. Younkin,et al. Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice , 1996, Science.
[40] G. Schellenberg,et al. Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease , 1996, Nature Medicine.
[41] B. Sommer,et al. Expression of APP in transgenic mice: a Comparison of neuron-specific promoters , 1996, Neurobiology of Aging.
[42] R. Mantegna,et al. Quantitative analysis of senile plaques in Alzheimer disease: observation of log-normal size distribution and molecular epidemiology of differences associated with apolipoprotein E genotype and trisomy 21 (Down syndrome). , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[43] B. Hyman,et al. The Lack of Accumulation of Senile Plaques or Amyloid Burden in Alzheimer's Disease Suggests a Dynamic Balance Between Amyloid Deposition and Resolution , 1993, Journal of neuropathology and experimental neurology.
[44] M. Albert,et al. Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. , 1989, JAMA.